London Daily

Focus on the big picture.
Monday, Jul 21, 2025

Covid-19: Novavax vaccine shows 89% efficacy in UK trials

Covid-19: Novavax vaccine shows 89% efficacy in UK trials

A new coronavirus vaccine has been shown to be 89% effective in large-scale UK trials.

The Novavax jab is the first to show in trials that it is effective against the new virus variant found in the UK, the BBC's medical editor Fergus Walsh said.

The UK has secured 60 million doses of the jab, which will be made in Stockton-on-Tees in north-east England.

Meanwhile, a single-dose vaccine developed by Janssen is 66% effective, trial results have shown.

Janssen, a company owned by Johnson & Johnson, is also investigating whether giving two doses will give either stronger or longer-lasting protection.

The company said its initial findings showed one dose prevented 85% of severe cases.

Both the Novavax and Janssen jabs will need to be reviewed by regulators before they can be used.

The PM welcomed the "good news", with doses of the Novavax jab expected to be delivered in the second half of this year if approved for use by the Medicines and Healthcare Products Regulatory Agency (MHRA), the government said.

The UK has so far approved three coronavirus vaccines for emergency use - one from Oxford University and AstraZeneca, another by Pfizer and BioNTech, and a third from drug firm Moderna.

The Novavax jab, which is given in two doses, was shown to be 89.3% effective at preventing Covid-19 in participants in its Phase 3 clinical trial in the UK, and around 86% effective at protecting against the new UK variant. The jab's efficacy against the original Covid-19 strain was calculated to be 95.6%.

The Phase 3 trials - the final stage before a vaccine is looked at by a regulator - enrolled more than 15,000 people aged between 18-84, of whom 27% were older than 65, US firm Novavax said.

In the South African part of the trial, where most of the cases were the South African variant of the virus, the vaccine was 60% effective among those without HIV.

Stan Erck, chief executive of Novavax, said the results from the UK trial were "spectacular" and "as good as we could have hoped", while the efficacy in South Africa was "above people's expectations".

He told the BBC the manufacturing plant in Stockton-on-Tees should be up and running by March or April, with the company hoping to get approval for the vaccine from the MHRA around the same time.

Minister Lucy Frazer told BBC Breakfast the government could not put an exact timeframe on when the Novavax jab might be approved as the regulation process is "out of our control".

Health Secretary Matt Hancock said the new vaccine would be "another weapon in our arsenal to beat this awful virus", if approved.

Prof Paul Heath, chief investigator of the UK Novavax trial, said the trial findings were "enormously exciting", particularly because of the jab's efficacy against the UK variant.



These extremely encouraging trial results suggest another powerful vaccine against coronavirus could soon be within reach.

It works in a slightly different way to the ones that are already available - but does the same job of teaching the body's immune system to recognise and fight the pandemic virus.

What is more, it appears to be effective against emerging and more infectious variants of coronavirus too - something scientists have feared might not be possible because the vaccines were all designed to match the original virus, not these new, mutated versions.

Protection against illness from the new UK variant was high - around 86%.

Even with the South Africa variant, which has undergone the most worrisome changes, it offered a level of protection similar to that given by flu shots against influenza.

England's chief medical officer Prof Chris Whitty said, if the jab is approved, it "increases our future resilience" against the virus.

Nadhim Zahawi, the UK minister responsible for the vaccine rollout, said he was "particularly thrilled" to see the positive results as he had taken part in Novavax's trials himself.

In total, the UK has ordered 100 million doses of the Oxford-AstraZeneca vaccine and 40 million of the Pfizer-BioNTech vaccine - both are currently being rolled out in the UK.

Another 17 million doses of the Moderna vaccine, which was approved by the MHRA in early January, are expected in the spring.

The aim is to give everyone in the top four priority groups - up to 15 million people - a first dose by mid-February.

Pfizer and Moderna vaccines rely on technology that has not been used in previous vaccines, but the Novavax jab uses a more traditional method of recreating part of the spike protein of the virus to stimulate the immune system.

Like the Oxford vaccine, the Novavax jab can be stored at regular fridge temperature - which means it can be distributed more easily.



More than 7.4 million people in the UK have so far received a first dose of a coronavirus vaccine, according to the latest government figures.

Meanwhile, the latest estimate for the UK's R rate from the government's scientific advisory group, Sage, is 0.7 to 1.1. It means that on average, every 10 people with the virus will infect between seven and 11 other people. Last week, the R rate was between 0.8 and 1.

The latest growth rate range is between -5% and 0%, indicating that the number of new infections is broadly flat or shrinking by up to 5% every day.

Separately, the EU's vaccine contract with AstraZeneca has been published, in a growing row over reduced supplies of their jab.

Kate Bingham, who used to chair the UK's Vaccine Taskforce, said the reason the UK had a good supply of vaccines compared with other countries was because of its ability to get clinical trials completed quickly and at a high standard through the NHS's registry - with some 400,000 volunteers signing up "before the US even started their Phase 3 studies".

The UK recorded a further 1,239 deaths within 28 days of a positive coronavirus test on Thursday. There have also been another 28,680 new infections.


Novavax chief executive: UK trial results are "spectacular"


Newsletter

Related Articles

0:00
0:00
Close
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
US Revokes Visas of Brazilian Corrupted Judges Amid Fake Bolsonaro Investigation
U.S. Congress Approves Rescissions Act Cutting Federal Funding for NPR and PBS
North Korea Restricts Foreign Tourist Access to New Seaside Resort
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
Flying Taxi CEO Reclaims Billionaire Status After Stock Surge
Epstein Files Deepen Republican Party Divide
Zuckerberg Faces $8 Billion Privacy Lawsuit From Meta Shareholders
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
SpaceX Nears $400 Billion Valuation With New Share Sale
Microsoft, US Lab to Use AI for Faster Nuclear Plant Licensing
Trump Walks Back Talk of Firing Fed Chair Jerome Powell
Zelensky Reshuffles Cabinet to Win Support at Home and in Washington
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Irish Tech Worker Detained 100 days by US Authorities for Overstaying Visa
Dimon Warns on Fed Independence as Trump Administration Eyes Powell’s Succession
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Jeff Bezos Considers Purchasing Condé Nast as a Wedding Gift
Ghislaine Maxwell Says She’s Ready to Testify Before Congress on Epstein’s Criminal Empire
Bal des Pompiers: A Celebration of Community and Firefighter Culture in France
FBI Chief Kash Patel Denies Resignation Speculations Amid Epstein List Controversy
Air India Pilot’s Mental Health Records Under Scrutiny
Google Secures Windsurf AI Coding Team in $2.4 Billion Licence Deal
Jamie Dimon Warns Europe Is Losing Global Competitiveness and Flags Market Complacency
South African Police Minister Suspended Amid Organised Crime Allegations
Nvidia CEO Claims Chinese Military Reluctance to Use US AI Technology
Hong Kong Advances Digital Asset Strategy to Address Economic Challenges
Australia Rules Out Pre‑commitment of Troops, Reinforces Defence Posture Amid US‑China Tensions
Martha Wells Says Humanity Still Far from True Artificial Intelligence
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
U.S. Resumes Deportations to Third Countries After Supreme Court Ruling
Excavation Begins at Site of Mass Grave for Children at Former Irish Institution
Iranian President Reportedly Injured During Israeli Strike on Secret Facility
EU Delays Retaliatory Tariffs Amid New U.S. Threats on Imports
Trump Defends Attorney General Pam Bondi Amid Epstein Memo Backlash
Renault Shares Drop as CEO Luca de Meo Announces Departure Amid Reports of Move to Kering
Senior Aides for King Charles and Prince Harry Hold Secret Peace Summit
Anti‑Semitism ‘Normalised’ in Middle‑Class Britain, Says Commission Co‑Chair
King Charles Meets David Beckham at Chelsea Flower Show
If the Department is Really About Justice: Ghislaine Maxwell Should Be Freed Now
NYC Candidate Zohran Mamdani’s ‘Antifada’ Remarks Spark National Debate on Political Language and Economic Policy
×